Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Orion Oyj - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Orion Oyj - Product Pipeline Review - 2014', provides an overview of the Orion Oyj's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Orion Oyj's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Orion Oyj including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Orion Oyj's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Orion Oyj's pipeline products Reasons to buy - Evaluate Orion Oyj's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Orion Oyj in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Orion Oyj's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Orion Oyj and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orion Oyj - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Orion Oyj and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Orion Oyj Snapshot 6 Orion Oyj Overview 6 Key Information 6 Key Facts 6 Orion Oyj - Research and Development Overview 7 Key Therapeutic Areas 7 Orion Oyj - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Orion Oyj - Pipeline Products Glance 15 Orion Oyj - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Orion Oyj - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Orion Oyj - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Orion Oyj - Drug Profiles 20 (budesonide + formoterol fumarate) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 (fluticasone propionate + salmeterol) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 levosimendan 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ODM-201 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 dexmedetomidine hydrochloride 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ODM-103 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ODM-104 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ODM-203 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ORM-10103 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Inhibit BET Bromodomain for Oncology 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecules for Pain 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Orion Oyj - Pipeline Analysis 33 Orion Oyj - Pipeline Products by Target 33 Orion Oyj - Pipeline Products by Route of Administration 34 Orion Oyj - Pipeline Products by Molecule Type 35 Orion Oyj - Pipeline Products by Mechanism of Action 36 Orion Oyj - Recent Pipeline Updates 37 Orion Oyj - Dormant Projects 41 Orion Oyj - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 deramciclane 42 nitecapone 42 ODM-102 42 ORM-10921 42 SEL-103 42 SEL-103194 43 Orion Oyj - Company Statement 44 Orion Oyj - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables Orion Oyj, Key Information 6 Orion Oyj, Key Facts 6 Orion Oyj - Pipeline by Indication, 2014 9 Orion Oyj - Pipeline by Stage of Development, 2014 10 Orion Oyj - Monotherapy Products in Pipeline, 2014 11 Orion Oyj - Combination Treatment Modalities in Pipeline, 2014 12 Orion Oyj - Out-Licensed Products in Pipeline, 2014 13 Orion Oyj - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Orion Oyj - Phase III, 2014 15 Orion Oyj - Phase II, 2014 16 Orion Oyj - Phase I, 2014 17 Orion Oyj - Preclinical, 2014 18 Orion Oyj - Discovery, 2014 19 Orion Oyj - Pipeline by Target, 2014 33 Orion Oyj - Pipeline by Route of Administration, 2014 34 Orion Oyj - Pipeline by Molecule Type, 2014 35 Orion Oyj - Pipeline Products by Mechanism of Action, 2014 36 Orion Oyj - Recent Pipeline Updates, 2014 37 Orion Oyj - Dormant Developmental Projects,2014 41 Orion Oyj - Discontinued Pipeline Products, 2014 42 Orion Oyj, Other Locations 45 Orion Oyj, Subsidiaries 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.